FLT3 and acute myeloid leukemia: Besides the detection of the most frequent and almost patient-specific FLT3-ITD (FLT3-internal tandem duplication) that can be found in approximately 25% of all AML patients, activating mutations located in the FLT3-TKD (FLT3-tyrosine kinase domain) are found in about 7% of patients at diagnosis [1,2].